Phase 2 Proof-of-Concept Study for ataluren in Nonsense Mutation Aniridia PTC Therapeutics’ STAR study is a Phase 2 proof-of-concept study of ataluren, an orally administered, first-in-class, protein restoration therapy for the treatment of nonsense mutation aniridia, a rare genetic disorder...